British-Swedish drug maker has gone from Beijing’s scrutiny to its praise, hailed as a sign of doing business in China.
After China probe, is AstraZeneca’s new US$2.5 billion plan a blueprint for foreign firms?
RELATED ARTICLES
British-Swedish drug maker has gone from Beijing’s scrutiny to its praise, hailed as a sign of doing business in China.
